Want Help
The results showed that the terminal body weight of ob/ob-GAN NASH mice increased to 70.01 1.11 g, equivalent to a gain of 9.25 1.09% relative to the initial weight
Initially developed by Novartis for treating sarcopenia, it was later licensed to Versanis Bio, and due to its significant weight loss (20.5%) and muscle preservation potential in overweight type 2 diabetes patients in phase II trials, it was acquired by Eli Lilly for $1.925 billion in 2023
These findings emphasize the need for further research to understand the differential effects of these medications
It is FDA-approved for adults and pediatric patients aged 12 and older with obesity or overweight and at least one weight-related comorbidity.13 Liraglutide lowers blood sugar by enhancing insulin release and reducing appetite, with studies demonstrating a 15% reduction in caloric intake and an average weight loss of 18.5 lbs.10,14,15 While its mechanism of action is similar to semaglutide, liraglutide differs in dose, frequency, and formulation and should not be used interchangeably
